Cellusion develops and manufactures induced pluripotent stem cell-derived corneal endothelial cells for bullous keratopathy therapy. Their technology enables minimally invasive cell therapy, addressing the donor shortage issue and reducing surgery time and complications. Founded in 2015 in Tokyo, Japan, Cellusion aims to provide novel therapies for all bullous keratopathy patients through their mass culture system of iPS cells origin corneal endothelial cells.